Form **8937**
(December 2017)
Department of the Treasury
Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

▶ See separate instructions.

OMB No. 1545-0123

Part I Reporting Issuer

1 Issuer's name YARROW BIOSCIENCE, INC . (FORMERLY KNOWN AS VYNE THERAPEUTICS INC.)	**2 Issuer's employer identification number (EIN)** 45-3757789

3 Name of contact for additional information TYLER ZERONDA	**4** Telephone No. of contact (203) 433-7577	**5** Email address of contact INFO@YARROWBIOSCIENCE.COM

6 Number and street (or P.O. box if mail is not delivered to street address) of contact 470 JAMES STREET, SUITE 007	**7** City, town, or post office, state, and ZIP code of contact NEW HAVEN, CT 06513

8 Date of action JULY 27, 2026	**9** Classification and description MERGER WITH YARROW BIOSCIENCES, INC

10 CUSIP number SEE LINE 19 BELOW	**11** Serial number(s)	**12** Ticker symbol SEE ATTACHMENT	**13** Account number(s)

Part II Organizational Action
Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶ SEE ATTACHMENT

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶ SEE ATTACHMENT

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶ SEE ATTACHMENT

Part II Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

18 Can any resulting loss be recognized? ▶ SEE ATTACHMENT

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

Sign Here

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature ▶ [signature] Date ▶ 09/03/26

Print your name ▶ TYLER ZERONDA Title ▶ CFO

Paid Preparer Use Only

Print/Type preparer's name	Preparer's signature	Date	Check ☐ if self-employed	PTIN
MATTHEW SCALITI	[signature]	09/03/26		P00960286

Firm's name ▶	RSM US LLP	Firm's EIN ▶	42-0714325
Firm's address ▶	333 THORNALL ST., 6TH FLOOR EDISON, NJ 08837	Phone no.	732-515-7300

Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054

Yarrow Bioscience, Inc. (formerly Vyne Therapeutics, Inc.)

EIN: 45-3757789
Attachment to Form 8937

The information contained herein is provided pursuant to the requirements of Section 6045B of the Internal Revenue Code of 1986, as amended (the “Code”). This attachment includes a general summary of certain U.S. federal income tax laws and regulations relevant to the Merger (as defined below) and the tax basis of Vyne Therapeutics, Inc. (the “Company”) and former Yarrow Bioscience, Inc. (“Pre-Merger Yarrow”) common stock, for a beneficial owner of Company and Pre-Merger Yarrow common stock (each a “Stockholder”) relating to the Merger. This attachment does not constitute tax advice and does not purport to be complete or to describe the consequences that may apply to particular categories of Stockholders. The Issuer does not provide tax advice to its Stockholders, and any example provided below is merely illustrative. Stockholders are urged to consult their own tax advisors regarding the particular consequences to them of the Merger, including the applicability and the effect of all U.S. federal, state, local, and foreign tax laws.

LINE 12 – VYNE prior to the merger; YARW following the merger/name change

LINE 14

PLEASE NOTE THIS FORM RELATES SOLEY TO THE MERGER OF VYNE THERAPEUTICS, INC. WITH FORMER YARROW BIOSCIENCES, INC. PLEASE REFER TO THE OTHER FILINGS ON THIS SITE TO DETERMINE THE EFFECT OF: (1) THE SPECIAL DIVIDEND TO FORMER VYNE THERAPEUTICS, INC SHAREHOLDERS; AND (2) THE 1-50 REVERSE STOCK SPLIT FOR FORMER VYNE THERAPEUTICS, INC. SHAREHOLDERS

a. **Merger Details** On July 27, 2026 (the “Closing Date”), Yarrow Bioscience, Inc., a Delaware corporation (formerly known as VYNE Therapeutics Inc., a Delaware corporation) (prior to the Closing Date, unless context otherwise requires, “VYNE” and, after the Closing Date, the “Company”), consummated the previously announced acquisition (the “Closing”) of Yarrow Bioscience, Inc., a Delaware corporation (“Pre-Merger Yarrow”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (the “Original Merger Agreement”), as amended by Amendment No. 1 thereto on January 30, 2026 (“Amendment No. 1” and, together with the Original Merger Agreement, the “Merger Agreement”), by and among the Company, Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Pre-Merger Yarrow. Pursuant to the Merger Agreement, Merger Sub merged with and into Pre-Merger Yarrow, with Pre-Merger Yarrow continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”) under the name “Yarrow Bioscience Operating Company Corp.” In connection with the completion of the Merger, VYNE changed its name to “Yarrow Bioscience, Inc.” The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”), and/or a transfer within the meaning of Section 351(a) of the Code.
b. **Exchange of Pre-Merger Yarrow stock for Vyne Stock** -- Following the Vyne 1 for 50 Reverse Stock Split, which occurred prior to the Closing, at the effective time of the Merger (the “Effective Time”), (i) each then-outstanding share of Pre-Merger Yarrow capital stock (the “Yarrow Capital Stock”) (including shares of Yarrow Capital Stock issued pursuant to the Pre-Closing Financing (as defined below) and Pre-Merger Yarrow’s Series A preferred financing described below and excluding shares of Yarrow Capital Stock held as treasury stock immediately prior to the Effective Time and any dissenting shares) was converted

into the right to receive a number of shares of VYNE common stock, par value $0.0001 (the "Company Common Stock"), calculated in accordance with the Merger Agreement (the "Exchange Ratio"), (ii) each option to purchase shares of Pre-Merger Yarrow common stock that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, ceased to represent a right to acquire shares of Pre-Merger Yarrow common stock and was converted into and became an option to purchase shares of Company Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement, and (iii) each then-outstanding and unexercised warrant to purchase shares of Pre-Merger Yarrow common stock was converted into and became a warrant to purchase shares of Company Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement.

   i. No fractional shares of Company Common Stock were issued in connection with the Merger, and no certificates or scrip for any such fractional shares were issued. Any fractional shares of Company Common Stock resulting from the conversion of shares of Yarrow Capital Stock (including shares of Pre-Merger Yarrow common stock issued in the Pre-Closing Financing) were treated as follows: (i) one share of Company Common Stock if the aggregate amount of fractional shares of Company Common Stock of any individual holder of Yarrow Capital Stock upon conversion equaled or exceeded 0.50 or (ii) no shares of Company Common Stock if the aggregate amount of fractional shares of Company Common Stock of any individual holder of Yarrow Capital Stock upon conversion was less than 0.50, with no cash paid for any fractional share eliminated by such rounding

c. **Effect of Merger for Former Vyne Shareholders** -- Each share of VYNE Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding and such shares, subject to the proposed reverse stock split, were unaffected by the Merger.

   i. Under the terms of the Merger Agreement, prior to the Effective Time, the board of directors of VYNE (the "Board") accelerated the vesting of all options to purchase VYNE common stock (the "Company Options") and VYNE restricted stock units (the "Company Restricted Stock Units"). Each then-outstanding Company Option with an exercise price per share equal to or less than the volume weighted average closing trading price of a share of Company Common Stock on The Nasdaq Stock Market LLC ("Nasdaq") for the five (5) consecutive trading days ending three (3) trading days prior to the Calculation Date (as defined in the Merger Agreement), as reported by Bloomberg L.P. (the "Company Closing Price" and such Company Options, "In-the-Money Company Options"), was cancelled at the Effective Time and such holder thereof received an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying the excess of the Company Closing Price over the exercise price per share of the Company Common Stock underlying such Company Option by the number of shares of the Company Common Stock underlying such Company Option. Each Company Option with an exercise price greater than the Company Closing Price was cancelled for no consideration. Immediately prior to the Effective Time, each holder of an accelerated Company Restricted Stock Unit was entitled to receive a number of shares of Company Common Stock equal to the number of vested and unsettled shares underlying such Company Restricted Stock Unit.

LINE 15

Q: What are the material U.S. federal income tax considerations of the Merger to U.S. Holders of VYNE capital stock?

A: VYNE stockholders will not sell, exchange or dispose of any shares of VYNE Common Stock as a result of the Merger. Thus, there will be no U.S. federal income tax considerations to VYNE stockholders as a result of the Merger.

Q: What are the U.S. federal income tax consequences of the Merger to U.S. Holders of In-the-Money VYNE Options?

A: Holders of In-the-Money VYNE Options will receive a cash payment upon the cancellation of their In-the-Money VYNE Options. Such cash payment generally will be included in a U.S. Holder's income as ordinary income when paid.

Q: What are the U.S. federal income tax considerations of the Merger to U.S. Holders of Yarrow Capital Stock?

A: The Merger is intended to (1) qualify as a "reorganization" within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "Code") and/or (2) an exchange of shares of Yarrow Capital Stock for VYNE Common Stock under Section 351(a) of the Code. As a result, assuming such treatment, a U.S. Holder of Yarrow Capital Stock will not recognize gain or loss upon the exchange of its Yarrow stock for VYNE stock.

LINE 16

N/A

LINE 17

Sections 354, 358, 351, 368(a) and 1001

LINE 18

a. Not applicable.

LINE 19

a. The transactions relate to a Stockholder's taxable year that includes the July 27, 2026 Merger date.

b. Part I, Box 10 – The CUSIP number for the Company common stock prior to the Reverse Stock Split was 92941V308; the CUSIP number for the Company common stock after the Reverse Stock Split is 92941V407.

c. Information contained within this Form 8937 should not be interpreted as tax advice. Stockholders are encouraged to consult with their own tax advisors regarding specific tax consequences of the Merger, based on their specific facts and circumstances.